id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-304791-wv4qu9xm	Carfora, Vincenzo	Anticoagulant treatment in COVID-19: a narrative review	2020-08-18		.txt	text/plain	3568	193	41	Besides the respiratory involvement, COVID 19 patients frequently develop a pro-coagulative state caused by virus-induced endothelial dysfunction, cytokine storm and complement cascade hyperactivation. [11] enrolled 183 consecutive COVID-19 patients and performed routine coagulation tests [PT, [8] In COVID-19-patients it is common to observe increased fibrinogen and D-Dimer levels Chen, 2020 [9] In COVID-19-patients it is common to observe variable levels of prothrombin time (PT), activated partial thromboplastin time (aPTT) and International standardized ratio (INR) Qin, 2020 [15] In COVID-19 the hyperinflammation mediated by IL-1, TNF-alfa and IL-6 leads to an increase of plasma concentrations of fibrinogen and plasminogen activator inhibitor-1 (PAI-1) Campbell, 2020 [19] In a murine model of MERS-CoV infection, increased concentrations of C5a and C5b-9 were found in sera and lung tissues. Moreover, patients with cardiovascular disease and dyslipidemia have high levels of circulating asymmetric di-methyl-arginine (ADMA) [28] , an analogue of L-arginine that inhibits NOS-3 activity [29] , and this leads to lower NO levels; this explains why endothelial dysfunction and the pro-coagulant state are more severe in this cohort of patients.	./cache/cord-304791-wv4qu9xm.txt	./txt/cord-304791-wv4qu9xm.txt